Shares of Prometheus Biosciences soared 70% in premarket trading on Monday after Merck & Co. announced that it would acquire the company in a $10.8 billion deal. The deal, announced Sunday, gives ...

Just days before a planned celebration of its new Rahway headquarters, Merck announced another milestone: It officially closed on its previously announced $10.8 billion acquisition of San Diego-based ...

Merck announced Sunday morning that it is purchasing Prometheus Biosciences for nearly $11 billion. As part of the definitive agreement, Merck will acquire Prometheus’ lead candidate, PRA023, an anti ...

Merck (MRK) is an American multinational pharmaceutical company worth just a hair under $300 billion. The company has a dividend yield of just over 2.5% and a higher valuation with an incredibly well ...

Pharma goliath, Merck MRK and Prometheus Biosciences, Inc RXDX, together announced entering a definitive agreement where the former is set to acquire the latter, through a subsidiary for $200 per ...

--Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. today announced that the companies have entered into a definitive agreement under which Merck, through a ...

April 16 (Reuters) - Merck & Co MRK.N has agreed to acquire Prometheus Biosciences Inc RXDX.O for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday. The ...

Prometheus Biosciences, which has been on a roll since last fall’s positive results in a Phase 2 trial for treatments for ulcerative colitis and Crohn’s disease, is being gobbled up by Merck for $10.8 ...

Merck said Sunday that it will acquire Prometheus Biosciences for $10.8 billion, adding a pipeline of experimental drugs to treat immune-related diseases. The deal values Prometheus at $200 per share, ...